9.6 C
Munich
Saturday, October 1, 2022

Lung Cancer Therapeutic Recent High Peak In The Healthcare Industry

Must read

What is Lung Cancer Therapeutic and How Big is the Industry

Cancer is a genetic disease that occurs as a result of abnormal cell growth. Lung cancer begins in the lungs’ tissues, most commonly in the cells that line the airways. Lung cancer is the common cause of cancer death globally. Persistent Cough, Shortness of Breath, Body Pain (Chest, Back, and Shoulders), Repeated Respiratory Infections, Fatigue, Blood Clots, and Sudden Weight Loss are some of the symptoms of lung cancer. Small and non-small cell lung cancers are the two types of lung cancer. According to GLOBOCAN 2020, lung cancer will remain the second most common cancer diagnosed and the leading cause of cancer mortality in 2020, with an estimated 2.2 million new cases and 1.8 million fatalities, accounting for approximately one in every ten (11.4%) cancer diagnoses and one in every five (18.0%) deaths.
The global lung cancer therapeutics market size in 2021 was $28.56 billion and will grow to reach $60.72 billion by 2030, growing at an 8.74% CAGR between 2021 and 2030.

Market dynamics

The risk factor for the development of lung cancer is cigarette smoking. Continuous tobacco smoke exposure can also cause lung cancer. Lung cancer treatment is effective with therapies like chemotherapy, radiotherapy, immunotherapy, surgery, and other methods.
Furthermore, increased funding for research and development of new drugs increased pollution due to rapid industrialization, and an increase in smokers are reasons for the rising prevalence of lung cancer.
Janssen Pharmaceutical Companies of Johnson & Johnson received FDA approval for Rybrevant as the first treatment for adult patients with non-small cell lung cancer in May 2021. Such product approvals also contribute to the study market’s growth over the forecast period.
However, the drug therapies’ side effects and the high cost of the therapies have restricted the market growth.

Key market trends

There are two types of primary lung cancer: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The most common of the two types of lung cancer is non-small cell lung cancer. According to the American Cancer Society 2019, non-small cell lung cancer accounts for 80% to 85% of all lung cancers. Large cell carcinoma, Adenocarcinoma, squamous cell carcinoma, and large cell carcinoma are the three main subtypes of non-small cell lung cancer.

According to a Cancer Treatment Centers of America article published in January 2022 on lung cancer types, lung adenocarcinoma is the most common type of lung cancer, accounting for 30% of all cases overall and approximately 40% of all non-small cell lung cancer occurrences.

According to the American Cancer Society, an estimated number of people suffering from 236,740 lung and bronchus cancers will undergo diagnosis in the United States in 2022, with 130,180 deaths. The majority of those cases are expected to be NSCLC. As a result, demand for cancer therapeutics will likely increase over the forecast period.

Market segmentation

• Based on Therapy, the industry is segmented into chemotherapy, radiation therapy, immunotherapy, targeted Therapy, and others. Chemotherapy dominates the market shares by Therapy. Chemotherapy utilizes anti-cancer (cytotoxic) medications to kill cancer cells. These work by preventing cancer cell growth. Chemotherapy is a common cancer treatment because cancer cells grow and spread faster than the rest of the body’s cells.

• By disease type, the industry is segmented into small cell lung cancer and non-small cell lung cancer. Non-Small Cell Lung Cancer accounts for a huge share of the market by Disease Type. The most common type of lung cancer is non-small cell (NSCLC). Non-small cell lung cancer (NSCLC) is of three types: squamous cell carcinoma (25% of lung cancers), Adenocarcinoma (40% of lung cancers), and large cell carcinoma (10% of lung cancers). According to the American Cancer Society 2019, NSCLC accounts for 80% to 85% of all lung cancers. Simultaneously, SCLC is responsible for 10% to 15% of cases.

• Regionally, North America is expected to lead the lung cancer therapeutics market share because of the increasing number of patients with lung cancer. Advanced therapeutics are becoming more popular in North America, Latin America, the Middle East, and Africa. In the Asia Pacific, however, there is a strong preference for chemotherapy. According to GLOBOCAN 2020, lung cancer is the leading cause of cancer death and morbidity in men, while it ranks third in women after breast and colorectal cancer in terms of incidence. North America has one of the highest age-standard incidence rates in the world.

Key players

AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb Company, Eli Lilly and Company, Hoffmann-La Roche, Merck & Co., Pfizer Inc., Allergan Inc., Teva Pharmaceutical Industries Ltd, Abbvie Inc., Johnson & Johnson (Janssen Pharmaceuticals), Amgen Inc., and Novartis AG are among the market participants.

Related Report

Cancer Monoclonal Antibodies Market Growth and Analysis: The global cancer monoclonal antibodies market size was $51.88 billion in 2021 and is predicted to reach $108.47 billion by 2030, at a CAGR of 8.54% throughout the forecasted period of 2021-2030.

- Advertisement -spot_img

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisement -spot_img

Latest article